nach oben

Current Sexual Health Reports

Erschienen in:

16.01.2019 | Clinical Therapeutics (B McCarthy and R Segraves, Section Editors)

New Treatments for Female Sexual Dysfunction: Are they Safe and Effective for Older Post-Menopausal Women?

verfasst von: Janelle Sobecki-Rausch, Stacy Tessler Lindau

Erschienen in: Current Sexual Health Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Several new modalities for treatment of female sexual function problems have been approved by the US Food and Drug Administration (FDA). This review summarizes current evidence about recently approved medications to inform treatment of sexual function problems in women older than 65 years.

Recent Findings

Published studies leading to FDA approval of treatment modalities were efficacy trials not widely applicable to the general population. The clinical effectiveness of these modalities remains unknown. Although some studies have included post-menopausal women, few have included women older than 65 years.

Summary

Health care providers need current information about safety and effectiveness of these new treatments for all women, including the fast-growing population of older post-menopausal women. Exclusion of older women from studies of treatments for female sexual function problems presents a barrier to treatment.

Ortman JM, Velkoff VA, Hogan H. An aging nation: the older population in the United States. Suitland: United States Census Bureau, Economics and Statistics Administration, US Department of Commerce; 2014.

Lindau ST, Schumm LP, Laumann EO, Levinson W, O'muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med. 2007;357(8):762–74.CrossRefPubMedPubMedCentral

Laumann EO, Waite LJ. Sexual dysfunction among older adults: prevalence and risk factors from a nationally representative US probability sample of men and women 57–85 years of age. J Sex Med. 2008;5(10):2300–11.CrossRefPubMedPubMedCentral

US Food and Drug Administration Drugs@FDA: FDA Approved Drug Products. www.accessdata.fda.gov/scripts/cder/daf. Accessed October 18, 2018.

Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). Philadelphia: American Psychiatric Pub; 2013.CrossRef

Kingsberg SA, Wysocki S, Magnus L, Krychman ML. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10(7):1790–9.CrossRefPubMed

Simon JA, Nappi RE, Kingsberg SA, Maamari R, Brown V. Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on north American postmenopausal women and their partners. Menopause. 2014;21(2):137–42.CrossRefPubMed

Soe LH, Wurz GT, Kao CJ, DeGregorio MW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Health. 2013;5(1):605–11.

Archer DF, Carr BR, Pinkerton JV, Taylor HS, Constantine GD. Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence. Menopause (New York, NY). 2015;22(7):786.CrossRef

10.

Bachmann GA, Komi JO, Group OS. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480–6.PubMed

11.

Portman DJ, Bachmann GA, Simon JA, Group OS. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6):623–30.CrossRefPubMed

12.

Rutanen E-M, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003;10(5):433–9.CrossRefPubMed

13.

Simon J. Efficacy and safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women. Menopause. 2012;19(12):1397–8.

14.

Simon J, Bachmann G, Goldstein S, Lin V, Portman D, Phelps M. Evaluation of the safety of daily ospemifene 60 mg for up to 1 year when used in the treatment of vulvar and vaginal atrophy in postmenopausal women. Climacteric. 2011;14(suppl 1):87.

15.

Simon JA, Lin VH, Radovich C, Bachmann GA, Group OS. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418–27.PubMed

16.

Cui Y, Zong H, Yan H, Li N, Zhang Y. The efficacy and safety of ospemifene in treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy: a systematic review and meta-analysis. J Sex Med. 2014;11(2):487–97.CrossRefPubMed

17.

Constantine G, Graham S, Portman DJ, Rosen RC, Kingsberg SA. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18(2):226–32.CrossRefPubMed

18.

Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005;31(1):1–20.CrossRefPubMed

19.

Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8(1):15–27.CrossRefPubMed

20.

Portman DJ, Brown L, Yuan J, Kissling R, Kingsberg SA. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study. J Sex Med. 2017;14(6):834–42.CrossRefPubMed

21.

Simon JA, Kingsberg SA, Shumel B, Hanes V, Garcia M Jr, Sand M. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21(6):633–40.CrossRefPubMed

22.

DeRogatis L, Clayton A, Lewis-D'Agostino D, Wunderlich G, Fu Y. Validation of the female sexual distress scale-revised for assessing distress in women with hypoactive sexual desire disorder. J Sex Med. 2008;5(2):357–64.CrossRefPubMed

23.

Clayton AH, Segraves RT, Leiblum S, Basson R, Pyke R, Cotton D, et al. Reliability and validity of the Sexual Interest and Desire Inventory–Female (SIDI-F), a scale designed to measure severity of female hypoactive sexual desire disorder. J Sex Marital Ther. 2006;32(2):115–35.CrossRefPubMed

24.

Portman DJ, Johnson D, Yuan J, Barbour K, Kissling R. Flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the PLUMERIA study. Menopause. 2016;23(12):1393.

25.

Jaspers L, Feys F, Bramer WM, Franco OH, Leusink P, Laan ET. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women: a systematic review and meta-analysis. JAMA Intern Med. 2016;176(4):453–62.CrossRefPubMed

26.

Joffe HV, Chang C, Sewell C, Easley O, Nguyen C, Dunn S, et al. FDA approval of flibanserin—treating hypoactive sexual desire disorder. N Engl J Med. 2016;374(2):101–4.CrossRefPubMed

27.

Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone). Menopause. 2015;22(9):950–63.CrossRefPubMed

28.

Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause. 2016;23(3):243–56.CrossRefPubMed

29.

Labrie F, Derogatis L, Archer DF, Koltun W, Vachon A, Young D, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy. J Sex Med. 2015;12(12):2401–12.CrossRefPubMed

30.

Society NAM. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause (New York, NY). 2007;14(3 Pt 1):355.

31.

Constantine GD, Simon JA, Pickar JH, Archer DF, Kushner H, Bernick B, et al. The REJOICE trial: a phase 3 randomized, controlled trial evaluating the safety and efficacy of a novel vaginal estradiol soft-gel capsule for symptomatic vulvar and vaginal atrophy. Menopause. 2017;24(4):409–16.CrossRefPubMedPubMedCentral

32.

•• Constantine GD, Bouchard C, Pickar JH, Archer DF, Graham S, Bernick B, et al. Consistency of effect with a low-dose, estradiol vaginal capsule (TX-004HR): evaluating improvement in vaginal physiology and moderate-to-severe dyspareunia in subgroups of postmenopausal women. J Women’s Health. 2017;26(6):616–23 Age-related efficacy analysis performed in a population of women 62 years or older. CrossRef

33.

Sobecki-Rausch JN, Brown O, Gaupp CL, editors. Sexual dysfunction in lesbian women: a systematic review of the literature. Seminars in reproductive medicine. Stuttgart: Thieme Medical Publishers; 2017.

34.

Singal AG, Higgins PD, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014;5(1):e45.CrossRefPubMedPubMedCentral

35.

Centers for Medicare and Medicaid Services CMS Fast Facts. https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/CMS-Fast-Facts/index.html. Accessed October 18, 2018.

36.

Centers for Medicare and Medicaid Services Prescription Drug Benefit Manual Chapter 6. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Part-D-Benefits-Manual-Chapter-6.pdf.

37.

Centers for Medicare and Medicaid Services Formulary Guidance CY19 Formulary Reference FIle https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/RxContracting_FormularyGuidance.html. Accessed October 28, 2018.

Titel: New Treatments for Female Sexual Dysfunction: Are they Safe and Effective for Older Post-Menopausal Women?
verfasst von: Janelle Sobecki-Rausch
Stacy Tessler Lindau
Publikationsdatum: 16.01.2019
Verlag: Springer US
Erschienen in: Current Sexual Health Reports / Ausgabe 1/2019
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI: https://doi.org/10.1007/s11930-019-00187-x

Neu im Fachgebiet Urologie

25.04.2024 | Nierenkarzinom | Nachrichten

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

New Treatments for Female Sexual Dysfunction: Are they Safe and Effective for Older Post-Menopausal Women?

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

The Vulvar Vestibule, a Small Tissue with a Central Position: Anatomy, Embryology, Pain Mechanisms, and Hormonal Associations

Cultural Differences in the Treatment of Sex Problems

Effect of Body Weight on Sexual Function in Men and Women

Pornography Use in Adult Mixed-Sex Romantic Relationships: Context and Correlates

Sexual Violence Identification and Women’s Sexual Well-Being

Dyspareunia in Women: Updates in Mechanisms and Current/Novel Therapies

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Stufenschema weist Prostatakarzinom zuverlässig nach

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

Update Urologie